Blog | IMPACT AD

Understanding frontotemporal dementia

IMPACT-AD study investigator Dr. Robin Hsiung talks about frontotemporal dementia on the Global TV News Health Matters series....

Perspectives on testing from persons with lived experience

Dementia Dialogue

Alzheimer Society webinar on biomarker testing

Join us January 25, 2023 at 2 pm pacific time for a webinar on Alzheimer's disease biomarker testing hosted by the Alzheimer Society of...

Who, what, where & when of Alzheimer's testing

Talking with podcaster Real Talk Ryan Jespersen about the new Canadian Alzheimer's disease biomarker testing program based at St. Paul's...

First-in-Canada testing program for Alzheimer’s

On July 1, 2021 the St. Paul's Hospital Clinical Laboratory in Vancouver launched the Alzheimer's disease biomarker testing program for...

Biomarker testing guides in multiple languages

Want to learn more about the biomarkers involved in Alzheimer's disease testing, and how cerebrospinal fluid is collected? Check out our...

Alzheimer's disease testing innovation

The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific...

2020 Alzheimer Update

At the 2020 Alzheimer Update, Dr. DeMarco and Dr. Hsiung discuss biomarker testing and therapies for Alzheimer's disease....

Dr. Stites talks to the New York Times about early diagnosis

"A diagnosis explains what's happening, why you're not remembering" In this interview, Dr. Stites talks about reducing the stigma around...

Changing the future for people affected by dementia

The Alzheimer Society of British Columbia interviews Dr. DeMarco about the development of diagnostic tests for Alzheimer's....

Brain Canada & Health Canada fund the IMPACT-AD study!

The IMPACT-AD ("Translating research into practice: Investigating the impact of Alzheimer's disease diagnostics in Canada") Study was...